Der Ausschuss für Humanarzneimittel (CHMP) der Europäischen Arzneimittelagentur (EMA) empfahl die Zulassung des makrozyklischen, hochrelaxativen Vueway® (Gadopiclenol) bei Erwachsenen und pädiatrischen Patienten ab 2 Jahren. MAILAND, 13. Oktober 2023 /PRNewswire/ — Bracco Imaging S.p.A.,…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.